GLP-1glp-1 receptor agonistsdpp-4 inhibitorshepatocellular carcinomatype 2 diabetes

Gut study compares GLP-1 agonists with DPP-4 inhibitors after liver cancer resection

The analysis looks at patients with type 2 diabetes following curative resection of hepatocellular carcinoma, a group with high recurrence risk.

By Maren Holt · Senior Reporter, GLP-1

Sep 28 20:00 ETSource: Gut

The wire

01Chen, Yang and colleagues report in Gut on outcomes with GLP-1 receptor agonists versus DPP-4 inhibitors after curative resection of hepatocellular carcinoma in type 2 diabetes.
02Oncology history increasingly shapes incretin prescribing decisions, and comparative data in post-resection liver cancer patients is scarce.
03Only the citation is available here; effect sizes, cohort size and whether the design was observational are not stated in the material at hand.

From the source

GLP-1 receptor agonists versus DPP-4 inhibitors after curative resection of hepatocellular carcinoma in patients with type 2 diabetes
Gut · 2026 Sep 29 · Chen CL, Yang WS et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42810850/